A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Lymphoma, B-Cell
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Richter's Transformation
- Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)